FDA Update 5/29/2011

The FDA has approved a couple new drugs this week. You can expect more information on them when and if I get more. 

FDA Approves Edurant (rilpivirine) in combination with other anti-retrovirals to treat HIV

Rilpivirine has been shown to effectively decrease viral load when combined with peginterferon alpha and ribavirin. It is contraindicated in pregnancy (of patient or patient's sexual parter), previous adverse reaction, history of anemia. Common side effects are anemia (regular CBCs should be performed), birth defects (two non-hormonal contraceptive forms should be used), itching, nausea, tiredness, anal problems, and taste changes. It may cause interactions with a number of HMG CoA Reductase Inhibitors (-statins), as well as a few other medications. More information is available in the medication guide.

FDA Approves Sutent (sunitinib) for treatment of inoperable or metastatic progressive neuroendocrine tumors in the Pancreas

It is contraindicated in hepatic impairment. Common side effects include hypertension, arrhythmia, bleeding, thyroid and adrenal suppression, liver damage, swelling, cough, diarrhea, lightening of the skin and hair, and others. More information is available in the medication guide.

Cheers,

C. Samuels